Asset
TAUROLIDINE
Revenue
| Product | Latest period | Revenue |
|---|---|---|
| DEFENCATH | Q4 2025 | $91.2M |
Each figure is the latest quarter this company reported for that product, a fourth quarter being the year less nine months when no filing states one. A figure belongs to the product it was reported for, so nothing here is summed and a substance in several products shows once per product.
Clinical trials (0)
No records yet.
FDA applications (1)
| Application | Approved | Type | Applicant |
|---|---|---|---|
| NDA 214520 | 2023-11-15 | NDA | CORMEDIX INC |
Marketed products (2)
- DEFENCATH
- DEFENCATH